Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations

Dementia and Geriatric Cognitive Disorders

Volumn 32, Issue 3, 2011, Pages 193-197

  Wallin, A ^a,b   Gothlin M ^a   Gustavsson, M ^a   Zetterberg, H ^a   Eckerstrom C ^a   Blennow, K ^a   Edman, A ^a   Lind, K ^a   Nordlund, A ^a   Rolstad, S ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Institute of Neuroscience and Psychiatry   (Sweden)

Author keywords

Cerebrospinal fluid biomarkers; Clinical dementia staging; Cognitive decline; Dementia; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; DISEASE PROGRESSION; EDUCATIONAL STATUS; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROFILAMENT PROTEINS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 80155135687     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000333034     Document Type: Article

References (35)

1. Reisberg B, Gauthier S: Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr 2008; 20: 1-16. (Pubitemid 350256071)
2. Bruscoli M, Lovestone S: Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004; 16: 129-140. (Pubitemid 38963102)
3. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P: Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 2008; 29: 1-11. (Pubitemid 350102708)
4. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W: Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 2010; 6: 11-24.
5. Hsiung GY, Sadovnick AD, Feldman H: Apolipoprotein e epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian study of health and aging. CMAJ 2004; 171: 863-867. (Pubitemid 39371553)
6. Wolf H, Grunwald M, Ecke GM, Zedlick D, Bettin S, Dannenberg C, Dietrich J, Eschrich K, Arendt T, Gertz HJ: The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl 1998; 54: 31-50. (Pubitemid 28539341)
7. Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1: 213-225. (Pubitemid 46589353)
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234. (Pubitemid 43238346)
9. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
10. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K: Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-627.
11. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426-436. (Pubitemid 37159153)
12. Wallin A, Sjogren M: Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 2001; 122: 1937-1949. (Pubitemid 32925104)
13. Bjerke M, Andreasson U, Rolstad S, Nordlund A, Lind K, Zetterberg H, Edman A, Blennow K, Wallin A: Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord 2009; 28: 348-356.
14. Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A: Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol 2010; 17: 377-382.
15. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population- based study in 85-year-olds. Dement Geriatr Cogn Disord 2003; 15: 169-176. (Pubitemid 36206647)
16. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005; 76: 1485-1490. (Pubitemid 41531690)
17. Befolkningsstatistik. Göteborg, Göteborgs Stad, 2009.
18. Reisberg B, Ferris SH, de Leon MJ, Crook T: Global Deterioration Scale (GDS). Psychopharmacol Bull 1988; 24: 661-663.
19. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M: Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 1996; 9: 185-199. (Pubitemid 27028870)
20. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the Executive Interview. J Am Geriatr Soc 1992; 40: 1221-1226.
22. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9(suppl 1):173-176, discussion 177-178.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
24. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23-30. (Pubitemid 30479402)
25. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology 1993; 43: 250-260. (Pubitemid 23060253)
26. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872. (Pubitemid 43970103)
27. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
28. APA: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Arlington, American Psychiatric Publishing, 1994.
29. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A: Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12: 255-260. (Pubitemid 350179256)
30. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231-245.
31. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and lateonset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680. (Pubitemid 29266465)
32. Blennow K, Ricksten A, Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Batsman S, Marcusson J, Nagga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L, Rymo L: No association between the alpha2-macroglobulin (a2m) deletion and Alzheimer's disease, and no change in a2m mrna, protein, or protein expression. J Neural Transm 2000; 107: 1065-1079.
33. Mitchell AJ, Monge-Argiles JA, Sanchez-Paya J: Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Pract Neurol 2010; 10: 202-207.
34. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746. (Pubitemid 47058377)
35. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in csf. J Neurochem 1996;67:2013-2018. (Pubitemid 26349676)